BioNTech SE Q3 2026 Earnings Recap

BioNTech shares rose 3.6% after earnings, with investors responding to encouraging lung-cancer data and progress toward pivotal trials. The pipeline remains the main catalyst; the transcript provides no new financial outlook or near-term commercial catalyst.

Key Takeaways

• Updated data for gotistobart showed median overall survival nearly doubled versus standard-of-care chemotherapy in a non-pivotal stage of its global phase III trial; the pivotal stage is ongoing.
• Pumitamig plus LSD showed encouraging early efficacy and manageable safety in small cell lung cancer, including first-line patients, but the data are early.
• BioNTech and Gilead agreed to evaluate pumitamig with a TROP2-directed ADC in a planned phase III trial for first-line metastatic PD-L1-low or -negative triple-negative breast cancer, subject to regulatory approval.
• BioNTech is running four registrational programs for pumitamig in non-small cell lung cancer and is using combination data to inform potential chemotherapy-free trials.
• CEO Uğur Şahin said this was his final earnings call; Guido Oelkers is expected to take office as CEO by February 1 at the latest.